Phase 1 Safety Study of HI-6 Dimethyl Sulfonate in Organophosphorus Poisoning via IV Bolus and Infusion in Healthy Volunteers

The primary objective of this study is to evaluate the **safety** of HI-6 dimethyl sulfonate (HI-6 DMS) when administered by intravenous bolus and infusion in healthy volunteers. This is clinically relevant as HI-6 DMS is intended for the treatment of patients poisoned with organophosphorus compounds, which are highly toxic and can lead to severe health consequences. Understanding the safety profile of HI-6 DMS in a controlled setting is crucial for its potential therapeutic use in emergency situations involving organophosphorus poisoning.

The clinical trial involves participants who are being treated for **organophosphorus compound poisoning**. The study population includes both male and female subjects, with an age range of 18 to 65 years. The participants are not considered part of a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no key inclusion or exclusion criteria have been specified.

The clinical trial is a **Phase 1**, randomized, double-blind, single-center, placebo-controlled study designed to evaluate the safety of HI-6 dimethyl sulfonate (HI-6 DMS) administered by intravenous bolus and infusion in healthy volunteers. The trial aims to assess the treatment of patients poisoned with **organophosphorus compounds**. The study will involve a single escalating weight-adjusted dose of the investigational product. The trial is expected to commence recruitment on November 13, 2023, and is estimated to conclude by December 31, 2023.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. The study design ensures that neither the participants nor the investigators are aware of the treatment assignments, maintaining the double-blind nature of the trial. Subsequent follow-up visits will be scheduled to monitor the participants' safety and collect necessary data. The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted.

The expected length of participant involvement will vary depending on the dosing schedule and follow-up requirements, but it is anticipated to be within the trial's overall duration. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or any other reason deemed necessary by the investigator to ensure participant safety. The trial's methodology and procedures are designed to rigorously evaluate the safety profile of HI-6 DMS while maintaining the highest ethical standards in clinical research.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The trial is scheduled to commence recruitment on November 13, 2023, with an estimated completion date of December 31, 2023. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy through various measures, which may include symptom improvement scores, biomarker levels, or other relevant clinical indicators. The methods for measuring and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes collected at predetermined timepoints. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.